Publications by authors named "Hannah H Hogan"
Mol Cancer Ther
July 2024
Article Synopsis
- Metastatic castration-resistant prostate cancer is still incurable, despite recent treatments, and tumors show increased glycolysis as they progress.
- The study introduces BKIDC-1553, a new small-molecule compound that inhibits glycolysis specifically in prostate cancer cells without causing severe toxicity, and demonstrates promising results in preclinical models.
- BKIDC-1553 shows effective growth inhibition in various prostate cancer models and has safety and pharmacokinetic properties that suggest it’s ready for clinical trials to treat advanced prostate cancer.
Article Synopsis
- Metastatic castration-resistant prostate cancer remains largely untreatable, but this study focuses on a new small molecule, BKIDC-1553, that inhibits glycolysis in cancer cells without significant toxicity.
- Researchers tested BKIDC-1553 across various prostate cancer models and found it effectively inhibits cell proliferation and shows promising results in preclinical trials, comparable to existing treatments like enzalutamide.
- The findings suggest that BKIDC-1553 has the potential for safe use in human clinical trials, paving the way for new treatment options for advanced prostate cancer patients.
